低剂量阿司匹林足以预防全关节置换术后静脉血栓栓塞:一项系统综述
低剂量与高剂量阿司匹林在症状性肺栓塞、深静脉血栓、90天死亡率或大出血方面无显著差异。阿司匹林疗程不足4周者大出血风险(1.59%)和90天死亡率(1.95%)高于4周疗程者(分别为0.15%和0.07%)。
要点
- 低剂量阿司匹林预防全关节置换术后VTE不劣于高剂量。
- 阿司匹林疗程不足4周者大出血和90天死亡风险更高。
- 不同阿司匹林疗程间肺栓塞和深静脉血栓发生率无显著差异。
核心结论
- 低剂量阿司匹林在全关节置换术后VTE预防中不劣于高剂量阿司匹林。
- 阿司匹林疗程不足4周的患者大出血和90天死亡风险高于疗程4周者。
研究设计与样本
- 系统综述,检索Ovid MEDLINE、EMBASE和PubMed截至2016年7月的文献。
- 纳入至少包含一个全关节置换术后以阿司匹林作为唯一化学预防队列的研究,报告症状性VTE或大出血、90天死亡率等次要结局。
主要发现
- 低剂量与高剂量阿司匹林组在症状性肺栓塞、症状性深静脉血栓、90天死亡率或大出血方面无显著差异。
- 阿司匹林疗程不足4周者大出血发生率为1.59%,疗程4周者为0.15%。
- 阿司匹林疗程不足4周者90天死亡率为1.95%,疗程4周者为0.07%,差异有统计学意义。
- 肺栓塞或深静脉血栓发生率与阿司匹林疗程之间无显著差异。
关键数值与推荐
- 美国骨科医师学会2007年指南推荐阿司匹林325 mg每日两次,持续6周。
- 阿司匹林疗程不足4周者大出血发生率1.59%,疗程4周者0.15%。
- 阿司匹林疗程不足4周者90天死亡率1.95%,疗程4周者0.07%。
临床怎么用
- 全关节置换术后可选用低剂量阿司匹林进行VTE预防,无需追求高剂量。
- 应确保阿司匹林预防疗程至少4周,以降低大出血和90天死亡风险。
局限性
- 大出血差异可能归因于过早停药或报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing total joint arthroplasty (TJA) are at risk of developing venous thromboembolism (VTE) without adequate prophylaxis. Since the American Academy of Orthopedic Surgeons issued guidelines in 2007 recommending aspirin 325 mg bis in die for 6 weeks, aspirin has been favored as the main VTE prophylaxis. However, the appropriate dose and duration of aspirin are not well-studied. This systematic review aims to identify any differences between high and low dose as well as duration for aspirin thromboprophylaxis after TJA as outlined by previous studies. METHODS: A search was performed using Ovid MEDLINE, EMBASE, and PubMed, including articles up to July 2016. Studies were included if they contained at least 1 cohort that underwent TJA with aspirin as the sole chemoprophylaxis and reported either (1) symptomatic VTE or (2) secondary outcomes such as major bleeding or 90-day mortality. RESULTS: Forty-five papers were included. There were no significant differences in symptomatic pulmonary embolism, symptomatic deep vein thrombosis, 90-day mortality, or major bleeding between patients receiving low-dose or high-dose aspirin. Patients treated with aspirin for <4 weeks had a higher risk of major bleeding (1.59%) vs patients treated for 4 weeks (0.15%), which may be attributed to premature cessation or differential reporting. Patients treated with aspirin for <4 weeks had a statistically higher 90-day mortality (1.95%) vs patients treated for 4 weeks (0.07%). There was no significant difference between incidence of pulmonary embolism or deep vein thrombosis and the durations of aspirin treatment. CONCLUSION: This review suggests that low-dose aspirin is not inferior to high-dose aspirin for VTE thromboprophylaxis in TJA patients. Additionally, patients treated with aspirin for less than 4 weeks may have a higher risk of major bleeding and 90-day mortality compared to patients treated for a longer duration.
引用
- Azboy I, Groff H, Goswami K, et al. Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. J Arthroplasty. 2019. PMID: 31733981. doi:10.1016/j.arth.2019.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。